Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

PURPOSE: This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation–associated breast cancer. PATIENTS AND METHODS: This single-arm phase II study enrolled patients wit...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Telli, Melinda L., Jensen, Kristin C., Vinayak, Shaveta, Kurian, Allison W., Lipson, Jafi A., Flaherty, Patrick J., Timms, Kirsten, Abkevich, Victor, Schackmann, Elizabeth A., Wapnir, Irene L., Carlson, Robert W., Chang, Pei-Jen, Sparano, Joseph A., Head, Bobbie, Goldstein, Lori J., Haley, Barbara, Dakhil, Shaker R., Reid, Julia E., Hartman, Anne-Renee, Manola, Judith, Ford, James M.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2015
נושאים:
ORIGINAL REPORTS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451172/
https://ncbi.nlm.nih.gov/pubmed/25847929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.0085
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים